December 17, 2015.
Reuters reports that Martin Shkreli, the controversial chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals, was arrested in New York today on securities fraud charges involving his former hedge fund, MSMB Capital Management, and a pharma company he previously headed, Retrophin Inc. A Reuters reporter witnessed Shkreli's arrest at the Murray Hill Tower Apartments in Manhattan, NY. He FBI agents escorted Shkreli, who was wearing a hoodie, into a car. FBI spokeswoman Kelly Langmesser later confirmed the arrests of both Shkreli and Evan Greebel, a former partner at law firm Katten Muchin Rosenmann, which acted as Retrophin's outside counsel. Turing and KaloBios have so far declined to comment on the news. See the Reuters report here.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.